Antineoplaston Therapy in Treating Patients With Multiple Myeloma
NCT00003511
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class
Stopped
Slow accrual
Conditions
Multiple Myeloma
Interventions
DRUG:
Antineoplaston therapy (Atengenal + Astugenal)
Sponsor
Burzynski Research Institute